KR101249707B1 - 투석액 및 이에 관련된 방법과 시스템 - Google Patents

투석액 및 이에 관련된 방법과 시스템 Download PDF

Info

Publication number
KR101249707B1
KR101249707B1 KR1020067010395A KR20067010395A KR101249707B1 KR 101249707 B1 KR101249707 B1 KR 101249707B1 KR 1020067010395 A KR1020067010395 A KR 1020067010395A KR 20067010395 A KR20067010395 A KR 20067010395A KR 101249707 B1 KR101249707 B1 KR 101249707B1
Authority
KR
South Korea
Prior art keywords
pyrophosphate
type compound
pharmaceutical composition
dialysate
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067010395A
Other languages
English (en)
Korean (ko)
Other versions
KR20070014110A (ko
Inventor
더블유. 찰스 오닐
코바 로마쉬빌리
Original Assignee
에모리 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에모리 유니버시티 filed Critical 에모리 유니버시티
Publication of KR20070014110A publication Critical patent/KR20070014110A/ko
Application granted granted Critical
Publication of KR101249707B1 publication Critical patent/KR101249707B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020067010395A 2003-10-28 2004-10-27 투석액 및 이에 관련된 방법과 시스템 Expired - Fee Related KR101249707B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51517403P 2003-10-28 2003-10-28
US60/515,174 2003-10-28
PCT/US2004/035541 WO2005044189A2 (en) 2003-10-28 2004-10-27 Dialysates and methods and systems related thereto

Publications (2)

Publication Number Publication Date
KR20070014110A KR20070014110A (ko) 2007-01-31
KR101249707B1 true KR101249707B1 (ko) 2013-04-05

Family

ID=34572815

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067010395A Expired - Fee Related KR101249707B1 (ko) 2003-10-28 2004-10-27 투석액 및 이에 관련된 방법과 시스템

Country Status (9)

Country Link
US (1) US20070148258A1 (https=)
EP (1) EP1682077A4 (https=)
JP (1) JP4838139B2 (https=)
KR (1) KR101249707B1 (https=)
CN (2) CN101094681A (https=)
AU (1) AU2004287440A1 (https=)
BR (1) BRPI0416088A (https=)
CA (1) CA2544235C (https=)
WO (1) WO2005044189A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8187467B2 (en) 2003-12-30 2012-05-29 Ajay Gupta Parenteral administration of pyrophosphate for prevention or treatment of phosphate or pyrophosphate depletion
US8771749B2 (en) 2007-10-05 2014-07-08 National University Corporation Chiba University Stable bicarbonate ion-containing drug solution
US7658952B2 (en) 2007-10-11 2010-02-09 Baxter International Inc. Dialysis solutions containing pyrophosphates
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
JP5258448B2 (ja) * 2008-08-12 2013-08-07 扶桑薬品工業株式会社 透析用製剤
AU2015200995B2 (en) * 2010-04-23 2016-09-08 Vantive Health Gmbh Methods and compositions for reducing or preventing vascular calcification during peritoneal dialysis therapy
WO2011133855A1 (en) * 2010-04-23 2011-10-27 Baxter International Inc. Methods and compositions for reducing or preventing vascular calcification during peritoneal dialysis therapy
CN102517635B (zh) * 2012-01-12 2014-12-24 中国科学院新疆理化技术研究所 化合物锂钾磷氧和锂钾磷氧晶体及其制备方法
EP2862583A1 (en) * 2013-10-17 2015-04-22 Gambro Lundia AB Perm selective membrane for treating vascular calcification in chronic hemodialysis patients
DE102015007842A1 (de) * 2015-06-18 2016-12-22 Fresenius Medical Care Deutschland Gmbh Dialyselösung
WO2018165132A1 (en) * 2017-03-06 2018-09-13 University Of Houston System Polyphosphates as inhibitors of calcium crystallization
IT201700085412A1 (it) * 2017-07-26 2019-01-26 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
IT201700089258A1 (it) 2017-08-02 2019-02-02 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di carenza di ferro
AU2018445164B2 (en) 2018-10-11 2025-05-29 Vifor (International) Ltd. Inositol phosphates for the treatment of ectopic calcification
IT201900007326A1 (it) 2019-05-27 2020-11-27 Alesco Srl Composizioni comprendenti acidi grassi cetilati e loro uso nel trattamento di artriti e stati infiammatori articolari
IT201900007311A1 (it) 2019-05-27 2020-11-27 Alesco Srl Procedimento per la preparazione di una composizione comprendente acidi grassi cetilati
CN118416279B (zh) * 2024-04-23 2025-09-02 大连医科大学附属第二医院 一种预防血管钙化的动静脉内瘘外用敷料及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102394A2 (en) 2001-06-18 2002-12-27 Neptune Technologies & Bioressources Inc. Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE216217T1 (de) * 1996-02-08 2002-05-15 Warner Lambert Co Zahnpflegemittel gegen zahnsteinbildung enthaltend hochlösliche pyrophosphate
US6689275B1 (en) * 1996-12-31 2004-02-10 Ajay Gupta Method and pharmaceutical composition for replacing iron losses in dialysis patients
US6779468B1 (en) * 1997-08-07 2004-08-24 Ajay Gupta Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
DE69734781T2 (de) * 1996-12-31 2006-07-20 Gupta, Ajay, Cerritos Verfahren und pharmazeutische zusammensetzung zum zuführen von eisen bei hämodialyse-und peritonealdialysepatienten
EP1009452A4 (en) * 1997-08-07 2004-03-31 Ajay Gupta WATER-SOLUBLE VITAMINS AND DIALYSIS SOLUTION CONTAINING NUTRIENTS
JP2003519183A (ja) * 2000-01-04 2003-06-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心臓および動脈の石灰化を抑制する低用量ビスホスホネートの使用
JP2002249433A (ja) * 2000-12-19 2002-09-06 Sumitomo Pharmaceut Co Ltd 血管石灰化抑制剤
US6524788B1 (en) * 2001-11-02 2003-02-25 Thomas L. Cantor Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US8187467B2 (en) * 2003-12-30 2012-05-29 Ajay Gupta Parenteral administration of pyrophosphate for prevention or treatment of phosphate or pyrophosphate depletion

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102394A2 (en) 2001-06-18 2002-12-27 Neptune Technologies & Bioressources Inc. Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Circulation Research Vol.87: e10-e17 (2000. 9. 29.) *
Nature Vol.212: 901-903(1966. 11. 26.) *
Proc. roy. Soc. Med. Vol.63: 876 (1970. 9.) *
Proc. roy. Soc. Med. Vol.63: 876 (1970. 9.)*

Also Published As

Publication number Publication date
CA2544235C (en) 2013-12-10
BRPI0416088A (pt) 2007-01-02
EP1682077A4 (en) 2009-07-01
KR20070014110A (ko) 2007-01-31
WO2005044189A2 (en) 2005-05-19
CN103054901A (zh) 2013-04-24
JP4838139B2 (ja) 2011-12-14
EP1682077A2 (en) 2006-07-26
WO2005044189A3 (en) 2007-06-14
CA2544235A1 (en) 2005-05-19
AU2004287440A1 (en) 2005-05-19
US20070148258A1 (en) 2007-06-28
JP2007523056A (ja) 2007-08-16
CN101094681A (zh) 2007-12-26

Similar Documents

Publication Publication Date Title
KR101249707B1 (ko) 투석액 및 이에 관련된 방법과 시스템
JP2007523056A5 (https=)
JP5919597B2 (ja) デオキシコール酸およびその塩類の製剤
WO2017042944A1 (ja) フィラデルフィア染色体陽性（Ｐｈ＋）急性リンパ性白血病（ＡＬＬ）の治療薬又は治療方法
KR20090094090A (ko) 치료를 위한 방법 및 조성물
CA3172535A1 (en) Cyclophilin inhibitors and uses thereof
JP2009532364A (ja) 腫瘍および疾患の治療におけるイノシトール−トリピロリン酸の使用
US20140179635A1 (en) Tumor eradication by inositol-tripyrophosphate
EP4313067A1 (en) Treatment of immune-related disorders, kidney disorders, liver disorders, hemolytic disorders, and oxidative stress-associated disorders using nrh, narh and reduced derivatives thereof
CN115335047B (zh) 用于治疗血管脂肪瘤的组合物
KR20210148078A (ko) 조직 관류 증가에 사용하기 위한 이노시톨 포스페이트 화합물
Remuzzi et al. Dissociation between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in rats
AU2020440809B2 (en) Compositions comprising 15-HEPE for treating or preventing hematologic disorders, and/or related diseases
JP6219430B2 (ja) デオキシコール酸およびその塩類の製剤
JP7474516B2 (ja) 化学プール薬剤、注射製剤、内服製剤、輸液製剤および透析装置
RU2358731C2 (ru) Cci-779 для лечения лимфомы из мантийных клеток
MXPA06004730A (en) Dialysates and methods and systems related thereto
WO2014159679A1 (en) Methods for using lubiprostone to absorb fluid from the subretinal space
JP2009522355A (ja) 腫瘍および疾患の治療におけるイノシトール−トリピロリン酸の使用
US20070049579A1 (en) Medicament having neovascularization promoting action
JP6594486B2 (ja) デオキシコール酸およびその塩類の製剤
Faget et al. Public Health Reports, December 11, 1942: Sulfanilamide in the treatment of leprosy
Nagura et al. Me3221, a surmountable angiotensin at1-receptor antagonist, prevents hypertensive complications in aged stroke-prone spontaneously hypertensive rats
SU1588420A1 (ru) Способ профилактики отторжени аллотрансплантированной почки
Faget et al. SULFANILAMIDE IN THE TREATMENT OF LEPROSY.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160328

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160328